Conclusion: 1. 70 % remained stable, but those reaching HGD all progressed to ACE (only in 50 % of the latter, HGD is recognized with H&E). 2. Methylation´s grade is higher in all diagnostic groups comparing to the control group, progressively increased as the dysplasia grade found with H&E, so it may be a good biomarker for neoplastic progression. Objective: In High Risk HPVs the expression of oncoprotein E6 is responsible for the degradation of p53, while E7 inactivates pRb and causes the progression to S phase of cell cycle, both sustaining the conversion to and the maintenance of malignancy. The aim of this study is to compare the performance in the detection of the E6 and E7 mRNA expression of HR-HPV using the NucliSENS Easy q test (bioMerieux) or HPV OncoTect (IncellDx) a test based on Flow cytometry-FISH method. Method: We enrolled 50 patients positive for HR-HPV DNA and/or pap smears. All subjects underwent a colposcopy histological evaluation and were tested both for the NucliSENS Easy q test and HPV OncoTect. Results: 31 out of 50 subjects resulted positive for RNA expression. The patients were divided into two cohorts based on the histological diagnosis: low grade lesions (CIN1) and high grade lesion (CIN2+). Patients with CIN1 were 26 with NucliSENS Easy q test and 13 with HPV Onco Tect, those with CIN2+ were 5 with either tests. Conclusion: These preliminary results suggest that HPV OncoTect have a better specificity than NucliSENS Easy q test, while more samples need to assess the difference in sensitivity.